Nothing Special   »   [go: up one dir, main page]

DK3198009T3 - Onkolytiske tumorvira og anvendelsesfremgangsmåder - Google Patents

Onkolytiske tumorvira og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK3198009T3
DK3198009T3 DK15843893.7T DK15843893T DK3198009T3 DK 3198009 T3 DK3198009 T3 DK 3198009T3 DK 15843893 T DK15843893 T DK 15843893T DK 3198009 T3 DK3198009 T3 DK 3198009T3
Authority
DK
Denmark
Prior art keywords
methods
tumor viruses
oncolytic
oncolytic tumor
viruses
Prior art date
Application number
DK15843893.7T
Other languages
English (en)
Inventor
Clodagh O'shea
Shigeki Miyake-Stoner
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of DK3198009T3 publication Critical patent/DK3198009T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15843893.7T 2014-09-24 2015-09-23 Onkolytiske tumorvira og anvendelsesfremgangsmåder DK3198009T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054724P 2014-09-24 2014-09-24
PCT/US2015/051745 WO2016049201A1 (en) 2014-09-24 2015-09-23 Oncolytic tumor viruses and methods of use

Publications (1)

Publication Number Publication Date
DK3198009T3 true DK3198009T3 (da) 2021-11-22

Family

ID=55581955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15843893.7T DK3198009T3 (da) 2014-09-24 2015-09-23 Onkolytiske tumorvira og anvendelsesfremgangsmåder

Country Status (11)

Country Link
US (1) US20170202893A1 (da)
EP (2) EP3198009B1 (da)
JP (3) JP6764859B2 (da)
KR (2) KR20230165385A (da)
CN (1) CN108064275A (da)
AU (2) AU2015320665B2 (da)
CA (1) CA2961748A1 (da)
DK (1) DK3198009T3 (da)
ES (1) ES2899913T3 (da)
PL (1) PL3198009T3 (da)
WO (1) WO2016049201A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
WO2016049201A1 (en) * 2014-09-24 2016-03-31 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use
WO2017062511A1 (en) * 2015-10-05 2017-04-13 Salk Instutitute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017223589B2 (en) * 2016-02-23 2023-08-03 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2018111767A1 (en) * 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
MX2019008921A (es) * 2017-01-30 2019-11-08 Epicentrx Inc Adenovirus recombinante de transgenes múltiples.
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
EP3773649A4 (en) * 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
AU2019251356A1 (en) * 2018-04-09 2020-11-05 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
CN113710810A (zh) * 2019-02-21 2021-11-26 安利舒免疫溶瘤技术公司 溶瘤腺病毒载体和使用方法
KR20220079551A (ko) * 2019-09-05 2022-06-13 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 종양 세포 붕괴성 아데노바이러스, cdk4/6 억제제 및 추가의 치료 활성제의 조합물에 의한 종양의 치료
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
KR20220153581A (ko) * 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 의 억제제 및 이의 사용 방법
WO2022236080A2 (en) * 2021-05-06 2022-11-10 Asimov Inc. Compositions and methods for adeno-associated viral production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
ATE546531T1 (de) * 2003-12-31 2012-03-15 Kalobios Inc Transaktivierungssystem für säugerzellen
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
KR101721725B1 (ko) * 2010-08-16 2017-03-31 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 아데노바이러스 조립 방법
CN110592123A (zh) 2012-03-13 2019-12-20 萨克生物研究学院 使用腺病毒和化学二聚体的选择性细胞寻靶
SG11201507393TA (en) * 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
US10647963B2 (en) * 2013-04-18 2020-05-12 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
WO2016049201A1 (en) 2014-09-24 2016-03-31 Salk Institute For Biological Studies Oncolytic tumor viruses and methods of use

Also Published As

Publication number Publication date
JP2024038030A (ja) 2024-03-19
AU2022203504A1 (en) 2022-06-09
PL3198009T3 (pl) 2022-01-24
EP3198009A4 (en) 2018-09-05
JP2017534263A (ja) 2017-11-24
EP4043021A2 (en) 2022-08-17
AU2015320665A1 (en) 2017-04-06
EP4043021A3 (en) 2022-11-23
JP7416423B2 (ja) 2024-01-17
AU2015320665B2 (en) 2022-06-16
KR20230165385A (ko) 2023-12-05
CN108064275A (zh) 2018-05-22
KR102608590B1 (ko) 2023-12-01
EP3198009B1 (en) 2021-09-08
ES2899913T3 (es) 2022-03-15
JP2021007392A (ja) 2021-01-28
US20170202893A1 (en) 2017-07-20
CA2961748A1 (en) 2016-03-31
KR20170063801A (ko) 2017-06-08
JP6764859B2 (ja) 2020-10-07
EP3198009A1 (en) 2017-08-02
WO2016049201A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
DK3198009T3 (da) Onkolytiske tumorvira og anvendelsesfremgangsmåder
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
HK1248106A1 (zh) Pd-1結合分子和其使用方法
DK3653221T3 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
IL250415B (en) Antibodies against pd-l and methods of using them
DK3400293T3 (da) Modificeret onkolytisk virus
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3221357T3 (da) Fælles letkæder og fremgangsmåder til anvendelse
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
PL3160498T3 (pl) Cząsteczki na bazie IL-15 i sposoby ich zastosowania
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3205650T3 (da) Egfr-hæmmer og fremstilling og anvendelse deraf
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3209308T3 (da) Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
BR112016016289A2 (pt) heteroaris e usos dos mesmos
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3218005T3 (da) Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3100050T3 (da) Immobiliserede proteiner og anvendelse deraf